{
    "study_metadata": {
        "pmid": "12345678",
        "title": "Mock Study: Lenvatinib vs. Sorafenib for HCC",
        "year": 2023,
        "journal": "Journal of Mock Oncology",
        "doi": "10.1000/jmo.2023.001",
        "study_design": "RCT",
        "phase": "Phase III",
        "sample_size_total": 954,
        "arms": ["Lenvatinib", "Sorafenib"],
        "comparator": "Sorafenib"
    },
    "experiments": [
        {
            "arm_name": "Lenvatinib",
            "treatment": {
                "name": "Lenvatinib",
                "category": "Systemic",
                "line_of_therapy": "first-line",
                "duration": "Until progression or unacceptable toxicity",
                "combination": false,
                "components": null
            },
            "bclc_baseline": {
                "tumor_burden": {
                    "nodules": ">3",
                    "largest_nodule_cm": null,
                    "vascular_invasion": true,
                    "extrahepatic_spread": true,
                    "afp_ng_ml": null,
                    "afp_gt_400": null
                },
                "child_pugh": {
                    "bilirubin_mg_dl": null,
                    "albumin_g_dl": null,
                    "inr": null,
                    "ascites": null,
                    "encephalopathy": null,
                    "class_letter": "A",
                    "score": 5
                },
                "performance_status": {
                    "ecog": 1
                }
            },
            "bclc_stage_reported": "C",
            "bclc_2025_cuse": {
                "mentioned": false,
                "cuse_criteria": null,
                "personalized_factors": null,
                "decision_logic": null
            },
            "results": {
                "response_criteria": "mRECIST",
                "os": {
                    "value": "13.6 months",
                    "ci": "95% CI, 12.0-15.2",
                    "p_value": "p<0.001",
                    "hr": 0.92,
                    "hr_ci": "0.79-1.06",
                    "follow_up": null,
                    "evidence_section": "Results - Survival Analysis",
                    "evidence_page": 5,
                    "table_figure": "Figure 2A",
                    "verbatim_excerpt": "Median overall survival was 13.6 months (95% CI, 12.0-15.2) in the lenvatinib group."
                },
                "pfs": {
                    "value": "7.4 months",
                    "ci": "95% CI, 6.9-8.8",
                    "p_value": "p<0.001",
                    "hr": 0.66,
                    "hr_ci": "0.57-0.77",
                    "follow_up": null,
                    "evidence_section": "Results - Survival Analysis",
                    "evidence_page": 6,
                    "table_figure": "Figure 2B",
                    "verbatim_excerpt": "Progression-free survival was 7.4 months (95% CI, 6.9-8.8) with lenvatinib."
                },
                "orr": {
                    "value": "24.1%",
                    "ci": null,
                    "p_value": null,
                    "hr": null,
                    "hr_ci": null,
                    "follow_up": null,
                    "evidence_section": "Results - Tumor Response",
                    "evidence_page": 7,
                    "table_figure": "Table 3",
                    "verbatim_excerpt": "The objective response rate was 24.1% in the lenvatinib arm."
                },
                "dcr": {
                    "value": null,
                    "ci": null,
                    "p_value": null,
                    "hr": null,
                    "hr_ci": null,
                    "follow_up": null,
                    "evidence_section": null,
                    "evidence_page": null,
                    "table_figure": null,
                    "verbatim_excerpt": null
                },
                "ttp": {
                    "value": null,
                    "ci": null,
                    "p_value": null,
                    "hr": null,
                    "hr_ci": null,
                    "follow_up": null,
                    "evidence_section": null,
                    "evidence_page": null,
                    "table_figure": null,
                    "verbatim_excerpt": null
                },
                "other": null
            },
            "safety": {
                "any_adverse_events_reported": true,
                "grade_3_4_events": [
                    {
                        "name": "Hypertension",
                        "grade": "3-4",
                        "frequency": "42%",
                        "notes": null
                    }
                ],
                "saes": null,
                "discontinuation_due_to_toxicity": "20%",
                "treatment_related_deaths": "1%",
                "narrative": "The most common grade 3 or 4 adverse event was hypertension (42%)."
            }
        },
        {
            "arm_name": "Sorafenib",
            "treatment": {
                "name": "Sorafenib",
                "category": "Systemic",
                "line_of_therapy": "first-line",
                "duration": "Until progression or unacceptable toxicity",
                "combination": false,
                "components": null
            },
            "bclc_baseline": {
                "tumor_burden": {
                    "nodules": ">3",
                    "largest_nodule_cm": null,
                    "vascular_invasion": true,
                    "extrahepatic_spread": true,
                    "afp_ng_ml": null,
                    "afp_gt_400": null
                },
                "child_pugh": {
                    "bilirubin_mg_dl": null,
                    "albumin_g_dl": null,
                    "inr": null,
                    "ascites": null,
                    "encephalopathy": null,
                    "class_letter": "A",
                    "score": 6
                },
                "performance_status": {
                    "ecog": 1
                }
            },
            "bclc_stage_reported": "C",
            "bclc_2025_cuse": {
                "mentioned": false,
                "cuse_criteria": null,
                "personalized_factors": null,
                "decision_logic": null
            },
            "results": {
                "response_criteria": "mRECIST",
                "os": {
                    "value": "12.3 months",
                    "ci": null,
                    "p_value": null,
                    "hr": null,
                    "hr_ci": null,
                    "follow_up": null,
                    "evidence_section": null,
                    "evidence_page": null,
                    "table_figure": null,
                    "verbatim_excerpt": null
                },
                "pfs": {
                    "value": "3.7 months",
                    "ci": null,
                    "p_value": null,
                    "hr": null,
                    "hr_ci": null,
                    "follow_up": null,
                    "evidence_section": null,
                    "evidence_page": null,
                    "table_figure": null,
                    "verbatim_excerpt": null
                },
                "orr": {
                    "value": "9.2%",
                    "ci": null,
                    "p_value": null,
                    "hr": null,
                    "hr_ci": null,
                    "follow_up": null,
                    "evidence_section": null,
                    "evidence_page": null,
                    "table_figure": null,
                    "verbatim_excerpt": null
                },
                "dcr": {
                    "value": null,
                    "ci": null,
                    "p_value": null,
                    "hr": null,
                    "hr_ci": null,
                    "follow_up": null,
                    "evidence_section": null,
                    "evidence_page": null,
                    "table_figure": null,
                    "verbatim_excerpt": null
                },
                "ttp": {
                    "value": null,
                    "ci": null,
                    "p_value": null,
                    "hr": null,
                    "hr_ci": null,
                    "follow_up": null,
                    "evidence_section": null,
                    "evidence_page": null,
                    "table_figure": null,
                    "verbatim_excerpt": null
                },
                "other": null
            },
            "safety": {
                "any_adverse_events_reported": true,
                "grade_3_4_events": [
                    {
                        "name": "Hand-foot skin reaction",
                        "grade": null,
                        "frequency": "11%",
                        "notes": null
                    }
                ],
                "saes": null,
                "discontinuation_due_to_toxicity": null,
                "treatment_related_deaths": null,
                "narrative": null
            }
        }
    ],
    "evidence_level": "high",
    "evidence_spans": [
        {
            "field_path": "study_metadata.pmid",
            "value_json": "\"12345678\"",
            "evidence_section": "Header",
            "evidence_page": 1,
            "table_figure": null,
            "verbatim_excerpt": "PMID: 12345678",
            "locator": null
        },
        {
            "field_path": "experiments[0].results.os.value",
            "value_json": "\"13.6 months\"",
            "evidence_section": "Results - Survival Analysis",
            "evidence_page": 5,
            "table_figure": "Figure 2A",
            "verbatim_excerpt": "Median overall survival was 13.6 months (95% CI, 12.0-15.2) in the lenvatinib group.",
            "locator": null
        }
    ]
}
